Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XSLJZ in Advanced Hepatocellular Carcinoma
NCT04562428Phase 4Completed
- Sponsor
- China Medical University Hospital
- Start
- Nov 2020
- Primary completion
- Dec 2020
- Modality
- HM (Herbal Medicine), Dietary Supplement, NPI (Non-Pharmacological Intervention)
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in hepatocellular carcinoma (HCC) and anorexia nervosa (AN) comparing XSLJZ with XSLJZ Placebo (2 arms). Primary endpoints: Body weight at 8 weeks, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 at 8 weeks and 3 more. Started Nov 2020; status: completed.
02
Drugs
Xiang Sha Liu Jun Zi Decoction
03
Conditions
hepatocellular carcinoma (HCC)anorexia nervosa (AN)
Beyond the preview
Go deeper on NCT04562428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04562428.